Group
CAR-T or Cell Therapy
Group Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | CAR-T or Cell Therapy |
| Mechanism of Action | TIL therapy |
| Drugs in group | Afamitresgene Autoleucel· Lifileucel |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic (RT debulks, induces ICD/cGAS-STING, ↑antigen/MHC-I, enhances trafficking/persistence), not a DNA-level sensitizer (Minn et al., Lancet Oncology, 2019; Hauth et al., JAMA Oncology, 2021). No in-field radiosensitization of normal tissue; theoretical adverse event concerns are immune/inflammatory (enhanced cytokine release or local inflammation).
The data above refer to patients treated with CAR-T or Cell Therapy as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.